Reports Q3 revenue $207.6M, consensus $218.5M. “The third quarter marked another period of robust growth in our hypercortisolism business. Once again, we had a record number of new prescriptions written for Korlym(R) and continued to add to our base of prescribers. Growing recognition among physicians of hypercortisolism’s true prevalence and the necessity of appropriate treatment is driving higher rates of screening and diagnosis. Our financial results don’t fully reflect this surge in demand, given capacity constraints at our previous specialty pharmacy vendor. We have modified our 2025 revenue guidance to $800 – $850 million. We added a new specialty pharmacy on October 1st and will add others in the coming months. We are confident that these additions will allow us to meet the increasing demand that we now see every month,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- CORT Upcoming Earnings Report: What to Expect?
- Promising Potential of Corcept Therapeutics’ Relacorilant in Ovarian Cancer Treatment Drives Buy Rating
- Corcept submits relacorilant marketing authorization application to EMA
- Corcept Therapeutics Ends Distribution Agreement with Optime
- Corcept Therapeutics falls -13.3%